A New Chondrogenic Differentiation Initiator With the Ability to Up-Regulate SOX Trio Expression

スポンサーリンク

概要

• 論文の詳細を見る

• During random screening for chondrogenic differentiation inducers, we found that Compound-1, 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-pyrazol-3-yl]benzene-1,3-diol, initiated chondrogenic differentiation of the chondroprogenitor cell line ATDC5. Compound-1 initiated chondrogenic differentiation of the mesenchymal stem cell line C3H10T1/2 in regions where cell aggregates formed and simultaneously inhibited adipogenic differentiation. In C3H10T1/2 cells, Compound-1 increased the expression of Sry-related high-mobility-group box transcription factors L-SOX5, SOX6, and SOX9 (SOX trio) more strongly than bone morphogenic protein (BMP)-2. cAMP-dependent protein kinase (PKA) inhibitors suppressed Compound-1–dependent L-SOX5 and SOX6 up-regulation. PKA inhibitors also suppressed the up-regulation of aggrecan mRNA induced by Compound-1, indicating that increases in L-SOX5 and SOX6 mRNA, in which the PKA pathway participates, are involved in the mechanisms behind the action of Compound-1. On the other hand, the SOX6 and aggrecan gene expression, which were up-regulated by BMP-2, were not affected by the PKA inhibitor. Compound-1 induced chondrogenic differentiation of bone marrow stromal cells and recovered cartilage matrix production by primary chondrocytes, which had been decreased by interleukin-1β. These results show the potential of Compound-1 to be a new cartilage repair agent for inducing chondrogenic differentiation via SOX trio up-regulation.

• 社団法人 日本薬理学会の論文

著者

• TAKIZAWA Masayuki

  Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd.

• FUSE Takako

  Pharmacology Research Laboratories I, Pharmacology Research Division, Takeda Pharmaceutical Company

• Noguchi Ken-ichi

  Pharmacology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company

• Watanabe Yasuko

  Pharmacology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company

関連論文

• The Chondroprotective Agent ITZ-1 Inhibits Interleukin-1β-Induced Matrix Metalloproteinase-13 Production and Suppresses Nitric Oxide-Induced Chondrocyte Death
• Pharmacokinetic and Pharmacodynamic Evaluations of Novel Oral Morphine Sustained Release Granules(Pharmacology)
• A New Chondrogenic Differentiation Initiator With the Ability to Up-Regulate SOX Trio Expression

スポンサーリンク